Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial
- PMID: 12888186
- DOI: 10.1016/s0924-977x(03)00032-4
Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial
Erratum in
- Eur Neuropsychopharmacol. 2004 Mar;14(2):173
Abstract
Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentaenoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (6.6 g/day) [corrected] with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P < 0.001). From the preliminary findings in this study, omega-3 PUFAs could improve the short-term course of illness and were well tolerated in patients with major depressive disorder.
Similar articles
-
Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial.J Clin Psychiatry. 2008 Apr;69(4):644-51. doi: 10.4088/jcp.v69n0418. J Clin Psychiatry. 2008. PMID: 18370571 Clinical Trial.
-
Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea.Ann Nutr Metab. 2015;66(2-3):141-148. doi: 10.1159/000377640. Epub 2015 Mar 24. Ann Nutr Metab. 2015. PMID: 25824637 Clinical Trial.
-
Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial.JACC Heart Fail. 2018 Oct;6(10):833-843. doi: 10.1016/j.jchf.2018.03.011. Epub 2018 Aug 8. JACC Heart Fail. 2018. PMID: 30098961 Clinical Trial.
-
Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?Lipids Health Dis. 2007 Sep 18;6:21. doi: 10.1186/1476-511X-6-21. Lipids Health Dis. 2007. PMID: 17877810 Free PMC article. Review.
-
Omega-3 fatty acids in the treatment of psychiatric disorders.Drugs. 2005;65(8):1051-9. doi: 10.2165/00003495-200565080-00002. Drugs. 2005. PMID: 15907142 Review.
Cited by
-
Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: review of recent studies and recommendations.Nutr Res Pract. 2021 Apr;15(2):137-159. doi: 10.4162/nrp.2021.15.2.137. Epub 2021 Jan 4. Nutr Res Pract. 2021. PMID: 33841720 Free PMC article. Review.
-
Improvement of major depression is associated with increased erythrocyte DHA.Lipids. 2013 Sep;48(9):863-8. doi: 10.1007/s11745-013-3801-7. Epub 2013 Jun 4. Lipids. 2013. PMID: 23733443 Clinical Trial.
-
Oiling the brain: a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan.Nutrients. 2010 Feb;2(2):128-70. doi: 10.3390/nu2020128. Epub 2010 Feb 9. Nutrients. 2010. PMID: 22254013 Free PMC article. Review.
-
Disentangling the Molecular Mechanisms of the Antidepressant Activity of Omega-3 Polyunsaturated Fatty Acid: A Comprehensive Review of the Literature.Int J Mol Sci. 2021 Apr 22;22(9):4393. doi: 10.3390/ijms22094393. Int J Mol Sci. 2021. PMID: 33922396 Free PMC article. Review.
-
Mood disorders and complementary and alternative medicine: a literature review.Neuropsychiatr Dis Treat. 2013;9:639-58. doi: 10.2147/NDT.S43419. Epub 2013 May 14. Neuropsychiatr Dis Treat. 2013. PMID: 23700366 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources